Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$203.15 USD

203.15
715,019

-0.73 (-0.36%)

Updated Jul 19, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why ResMed (RMD) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

by Zacks Equity Research

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

Charles River (CRL) Could be an Apt Pick Right Now: Here's Why

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.

Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial

by Zacks Equity Research

Neogen (NEOG) instills optimism among investors with its strategic progress and a string of product launches.

Omnicell (OMCL) Banks on Product Launches, Global Growth

by Zacks Equity Research

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Zacks.com featured highlights include ResMed, Badger Meter, Leidos and Ingersoll Rand

by Zacks Equity Research

ResMed, Badger Meter, Leidos and Ingersoll Rand are part of the Zacks Screen of the Week article.

Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs

by Zacks Equity Research

Thermo Fisher (TMO) has launched biobased solutions to help reduce the climate impact on the manufacturing of therapies.

Tirthankar Chakraborty headshot

4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR

by Tirthankar Chakraborty

Stocks such as ResMed (RMD), Badger Meter (BMI), Leidos (LDOS) and Ingersoll Rand (IR) are currently exhibiting superb earnings growth.

Is It the Right Time to Hold Labcorp (LH) in Your Portfolio?

by Zacks Equity Research

Labcorp's (LH) concentrated development in high-growth areas and strategic partnerships appear encouraging.

Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi

by Zacks Equity Research

Tandem Diabetes (TNDM) unveils survey results of the new Tandem Mobi insulin delivery system, underscoring its potential to significantly enhance the quality of life for people with diabetes

Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down

by Zacks Equity Research

An increasingly challenging pharmacy industry and consumer environment hurt Walgreens Boots' (WBA) bottom line in the third quarter of fiscal 2024.

Is it Wise to Hold Teleflex (TFX) Stock in Your Portfolio Now?

by Zacks Equity Research

Teleflex (TFX) holds strong momentum in the Interventional arm and a favorable solvency. Yet, macroeconomic impacts and competitive environment trigger concerns.

QIAGEN (QGEN) Backs New AAP Guidelines Supporting QFT-Plus Test

by Zacks Equity Research

QIAGEN (QGEN) supports the new TB screening guidelines from AAP, recommending IGRA tests like QFT-Plus to screen at-risk children of all ages.

Three Reasons to Retain Merit Medical (MMSI) Stock for Now

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Sheraz Mian headshot

Top Research Reports for NVIDIA, Amazon.com & UnitedHealth

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Amazon.com, Inc. (AMZN) and UnitedHealth Group Incorporated (UNH).

Thermo Fisher's (TMO) New Launch Speeds Up pDNA Purification

by Zacks Equity Research

Thermo Fisher (TMO) introduces the Thermo Scientific KingFisher PlasmidPro, the fully automated maxi-scale pDNA purification system.

Charles River's (CRL) RMS Growth Aids Amid FX Headwind

by Zacks Equity Research

Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.

Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Bruker's (BRKR) Strategic Buyouts Aid Amid Macroeconomic Woes

by Zacks Equity Research

Bruker's (BRKR) NANO Life Science fluorescence microscopy is gaining from product innovation and research demand, further bolstered by the addition of Inscopix's neuroscience research tools.

Boston Scientific (BSX) DBS Programming Software Gets CE Mark

by Zacks Equity Research

Boston Scientific (BSX) secures CE Mark for the DBS image-guided programming software, Vercise Neural Navigator 5.

Is It Apt to Hold Quest Diagnostics (DGX) Stock for Now?

by Zacks Equity Research

Strength in the core business bodes well for Quest Diagnostics (DGX). However, mounting debt levels and reduced COVID-19 testing revenues pose concerns.

Here's Why You Should Retain Inari Medical (NARI) for Now

by Zacks Equity Research

Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

by Zacks Equity Research

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.